Abstract
BackgroundClinical trials of the anti-IL-17A antibody secukinumab demonstrated the crucial role of IL-17A cytokine in the pathogenesis of spondyloarthritis (SpA), however, its cellular source in this condition remains controversial. Group...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
